Chronic kidney disease (CKD) is a major global health concern, and the uremic state is highly associated with fibrogenesis in several organs and tissues. Fibrosis is characterized by excessive production and deposition of extracellular matrix proteins with a detrimental impact on organ function. Another key feature of CKD is the retention and subsequent accumulation of solutes that are normally cleared by the healthy kidney. Several of these uremic retention solutes, including indoxyl sulfate and p-cresyl sulfate, have been suggested to be CKD-specific triggers for the development and perpetuation of fibrosis. The purpose of this brief review is to gather and discuss the current body of evidence linking uremic retention solutes to the fibrotic response during CKD, with a special emphasis on the pathophysiological mechanisms in the kidney.
Introduction
The kidneys are essential for the clearance of (metabolic) waste products. And even though the primary cause of kidney disease (either acute or chronic) is often related to direct injury, e.g., inflammatory damage in the case of glomerulonephritis and pyelonephritis, or hypoperfusion, ischemia, and toxic damage, this will ultimately result in a reduced renal function. When the kidneys fail to purify the body of metabolic end-products, a host of substances that are normally excreted into the urine are retained. This condition is called uremia, after the first recognized and most abundant retention product, urea. Many uremic retention solutes are biologically active and exert toxicity, affecting the functional capacity of almost every organ system in the body, resulting in the complex clinical picture of uremia (1) . Currently, uremic retention products are most often classified according to their removal pattern by dialysis, which is, up to now, the most frequently applied method to reduce solute levels in patients with endstage renal disease (ESRD). Three major groups are considered: (1) small water-soluble compounds, molecular weight (MW) <500 D, which are easy to remove by any type of dialysis; (2) larger middle molecules, mostly peptides, MW >500 D, which can only be cleared by dialyzers containing large pore membranes (high flux dialysis); and (3) protein-bound compounds, mostly with a low MW (<500 D), these solutes are difficult to remove by any type of dialysis, as protein binding hampers their clearance. Especially this class of retention solutes greatly contributes to comorbidities, such as organ fibrosis, observed in chronic kidney disease (CKD) patients.
Fibrosis and Uremia: Clinical Aspects
Fibrosis is a process whereby functional tissue is replaced by connective tissue. Once this phenomenon exceeds the level of physiological repair, it will result in loss of organ architecture as well as loss of functional tissue. Causes may be local damage, e.g., trauma, infection, or ischemia, but also more diffuse conditions, like systemic inflammation. In what follows, we will summarize the clinical consequences of fibrotic changes in uremia.
Renal Fibrosis
As stated above, kidney disease is often due to direct injury, yet in many cases this initial insult will initiate fibrogenesis, especially when regeneration as healing process is inadequate (2) . The kidney is a complex organ containing a wide variety of cells that constitute the glomeruli, tubules, interstitium, and capillaries (3) . And the initial site of injury determines the subsequent pathology, e.g., glomerular IgA deposition will cause glomerular fibrosis, whereas infections or proteinuria will provoke tubulointerstitial fibrosis (3) . Still, irrespective of etiology, the subsequent fibrotic response will ultimately affect the functional capacities of the kidney, with uremia as one of the consequences. To cope with this problem, many strategies have been developed in hopes of slowing down or even reversing fibrogenesis (4) . Although several studies have been successful at the pre-clinical level, only limited advances have been made at this time in the translation of these findings to the level of patient treatment (4) . In addition, in the analysis of the urinary proteome related to CKD and CKD progression, a marked positive correlation appears with collagen or matrix protein fragments, which via a bottom-to-top approach confirms the pathophysiological role of fibrosis in the functional disturbance of kidneys and other tissues in patients with CKD (5).
Cardiac Fibrosis
Similar to the kidney, fibrosis of the heart and its valves depends on a host of damaging processes, such as ischemia or inflammation, with heart failure as the functional resultant. Many of the factors that cause kidney failure, e.g., hypertension and diabetes, concurrently promote cardiac fibrosis (6, 7), a condition induced by uremic retention solutes as well (8, 9) . In its turn, the ensuing cardiac failure causes hypoperfusion and ischemia of the kidneys, which is causative for uremia.
The Cardio-Renal Axis
All these elements together result in a close interaction of renal and cardiac dysfunction, often termed, correctly or incorrectly, cardiorenal syndrome (10, 11) . Nevertheless, there is no debate that kidney and heart dysfunction are closely intertwined, resulting in a high cardiovascular burden in renal failure patients (12, 13) .
Fibrosis of Other Organ Systems
It seems conceivable that uremia at large is a profibrotic condition, which may be detrimental for organ systems other than the kidney and heart. A study in CKD rats demonstrated the presence of fibrosis in the peritoneal membrane, an organ system not directly involved in hemodynamic homeostasis, within 6 weeks (14) .
The most clinically relevant organ system next to the heart and the kidneys is the vascular bed. Vessel stiffness, a key pathophysiological feature of uremia, and at least in part the consequence of fibrosis (15) , results in systolic hypertension, diastolic hypoperfusion, a diminished physiologic response to orthostasis and volume loss, and an enhanced risk of cardiovascular events such as myocardial ischemia and ischemic and hemorrhagic stroke (16) .
Thus, it is clear that organ fibrosis is a key feature of CKD, yet the pathophysiological mechanisms underlying the fibrotic response during uremia remain to be fully elucidated.
Uremic Solutes and Renal Fibrosis
Fibrosis is the end result of a complex cascade of cellular and molecular responses initiated by organ damage (3). And even though there is a range of organ-specific triggers, the fibrotic process and associated signaling pathways are highly conserved between different organs (3). Furthermore, in recent years, epithelial-to-mesenchymal transition (EMT) has emerged as a leading, yet highly debated, hypothesis for the origin of collagenous matrix-producing myofibroblasts that contribute to the fibrotic response (17) (18) (19) (20) (21) . Renal fibrosis ends in uremia, yet uremia per se will also further enhance the fibrotic process, because of the direct biological effects of uremic toxins. In a recent systematic review on the toxicity of two uremic retention products, e.g., indoxyl sulfate and p-cresyl sulfate, of the 27 retrieved highquality studies, at least five demonstrated a direct link to EMT and/or kidney fibrosis (22) . Therefore, the remainder of this review will delineate the profibrotic impact of several uremic solutes on the kidney (summarized in Table 1 ).
TGF-β β β Signaling Pathway in CKD
Transforming growth factor (TGF)-β is one of the key factors driving the fibrotic response in most organs. Binding of TGF-β to a serine-threonine kinase type II receptor results in the recruitment and phosphorylation of a type I receptor, which in turn phosphorylates SMADs thereby initiating a host of signaling cascades (3, 23) . TGF-β is synthesized and secreted by inflammatory cells and a variety of effector cells, and activation of the pathway results in the formation and deposition of extracellular matrix proteins (3). In 1992, the role of TGF-β in renal fibrosis was still uncertain (24) , yet in the following years more and more studies demonstrated the involvement of this factor in renal fibrogenesis (25) (26) (27) . More recently, the interplay between uremic retention solutes, such as indoxyl sulfate and p-cresyl sulfate, and TGF-β has gained more scientific attention (28, 29) .
Impact of Indoxyl Sulfate on Fibrogenesis
Indoxyl sulfate is a small organic aromatic polycyclic anion derived from dietary tryptophan that has extensively been studied in conjunction with CKD-associated cardiovascular disease (22) , and it is reported that this uremic solute can induce vascular calcification and correlates with coronary artery disease and mortality (30) (31) (32) . Indoxyl sulfate is thought, however, to also contribute to a plethora of pathologies observed in dialysis patients, including tubulointerstitial inflammation and whole-kidney damage (22) . Although the contribution of EMT to fibrosis remains controversial, phenotypic alterations reminiscent of EMT, also referred to as epithelial phenotypic changes (EPC), might play a role in the fibrotic response as well as disease progression (40, 41) . Several studies have demonstrated that indoxyl sulfate induces EMT, as demonstrated by a reduced expression of E-cadherin and zona occludens (ZO)-1, and increased expression of α-SMA in rat kidney as well as rat proximal tubular (NRK-52E) cells (42, 43) . Furthermore, Sun et al. reported that treatment with indoxyl sulfate increased the expression of the EMT-associated transcription factor Snail, concurrent with an elevated expression of fibronectin and α-SMA as well as a diminished expression of E-cadherin in both mouse kidneys and murine proximal tubular cells (39) . Similar effects of indoxyl sulfate have also been observed in human renal cell models (42, 44) .
Renal cells can become senescent due to a variety of (stress) triggers, including aging, and these cells, while in growth arrest, can contribute to renal fibrosis by secreting profibrotic cytokines and growth factors (45) . It has been demonstrated that exposure of HK-2 cells to indoxyl sulfate resulted in an increased expression of p53 and p65, and augmented β-galactosidase activity (46, 47) , indicating that indoxyl sulfate induces senescence.
Lastly, the renoprotective anti-aging factor klotho, which is involved in a myriad of homeostatic processes (48-50), might mitigate renal fibrosis by suppressing TGF-β signaling and vice versa, deficient klotho expression may accelerate senescence and fibrosis (51, 52). Adijiang et al. reported that in both Dahl salt-resistant normotensive and Dahl salt-sensitive hypertensive rats, treatment with indoxyl sulfate resulted in lower gene expression of klotho (53) . These findings were corroborated by the study of Sun and colleagues showing that indoxyl sulfate suppressed klotho expression in murine renal proximal tubules as well as HK-2 cells (54) .
Taken together, it is evident that indoxyl sulfate can contribute to renal fibrogenesis via an array of pathophysiological mechanisms (Figure 1) , e.g., ROS production, stimulating expression of the profibrotic factor TGF-β, induction of EMT/EPC, promoting cellular senescence and by reducing klotho expression.
Profibrotic Activity of Other Protein-Bound Solutes
Next to indoxyl sulfate, several other uremic solutes have been linked to renal fibrosis, most prominently the p-cresol metabolite, p-cresyl sulfate (22, 29) . p-Cresol is formed by colonic bacteria from dietary tyrosine and this parent compound is either conjugated to sulfate or glucuronic acid giving rise to circulating p-cresyl sulfate or p-cresyl glucuronide (55) . The main profibrotic effect currently described for p-cresyl sulfate is the induction of TGF-β (protein) expression. Sun et al. reported that exposure of murine renal proximal tubular cells to p-cresyl sulfate resulted in an increased expression of TGF-β and SMAD phosphorylation, concurrent with the induction of EMT (39) . Conversely, in human conditionally immortalized renal proximal tubule epithelial cells, p-cresyl sulfate failed to induce EMT, whereas p-cresyl glucuronide did promote phenotypical changes associated with EMT (56). Furthermore, Watanabe et al. showed a ROS-dependent production and secretion of TGF-β protein in HK-2 cells upon treatment with p-cresyl sulfate (57) . Moreover, they reported that p-cresyl sulfate increased the gene expression of TIMP-1 and COL1A1 (57) . And, similar to indoxyl sulfate, it has been demonstrated that p-cresyl sulfate mitigated the expression of klotho in both murine and human renal cell models (54) .
Two other widely studied uremic solutes are hippuric acid and indole-3-acetic acid. Both protein-bound compounds have deleterious effects on normal renal (metabolic) functioning (58, 59 ), yet there is scant evidence for their potential impact on fibrosis. Satoh and colleagues demonstrated that treatment with either hippuric acid or indole-3-acetic acid induced glomerular sclerosis in rats (60) . And indole-3-acetic acid stimulated interstitial fibrosis (60) . Also, it has been reported that indole-3-acetic acid activated the TGF-β pathway in HK-2 cells, as illustrated by an increased expression of PAI-1 (28) .
Thus, several of the protein-bound uremic retention solutes, although chemically very diverse entities, can elicit similar toxic effects thereby promoting renal fibrosis. Yet, the majority, if not all, of this evidence has been obtained experimentally in animals or by in vitro studies, whereas clinical studies on this aspect are virtually absent. Therefore, far more (clinical) research is needed to fully characterize the possible profibrotic effects of the more than 150 cataloged uremic retention solutes.
New Kids on the Block
Next to the widely studied protein-bound uremic toxins, several other lesser-known retention solutes might play a role in renal fibrosis, for instance leptin and marinobufagenin (MBG).
Leptin (from the Greek word leptos, meaning "thin") is a product of the obese gene, identified in 1994 (61), and is secreted by adipocytes. Activation of its signaling pathway in the hypothalamus reduces food intake and increases energy expenditure. This adipocytokine is eliminated from the circulation via the kidneys mainly by metabolic degradation in the tubules (62) . And it has been reported that serum leptin levels are increased in CKD and ESRD patients (63, 64) . The mechanisms underlying leptin retention are complex as reviewed by Alix et al.: decreased renal clearance, increased fat mass, hyperinsulinemia, and low-grade chronic inflammation all contribute to hyperleptinemia in CKD patients (65) . Furthermore, it has been reported by Wolf and colleagues that leptin plays a role in the progression of renal fibrogenesis (66) . They demonstrated that leptin triggers glomerular endothelial cell proliferation via TGF-β. In addition, Briffa et al.
reported that leptin increased TGF-β production and secretion in opossum kidney proximal tubule cells (67) . Furthermore, it is shown that leptin stimulates COL1A1 production in renal interstitial (NRK-49F) fibroblasts (68) . Moreover, hyperleptinemia is associated with increased blood pressure, a known risk factor for renal fibrosis, and additional deleterious (potential profibrotic) effects of this adipocytokine have been described in experimental and clinical studies (69, 70) . Noteworthy, two classes of compounds with similar damaging effects on the cardiovascular system as leptin are dimethylarginines and advanced glycation end-products; however, more studies are needed to unveil the suspected profibrotic potential of these compounds. For an overview of the toxicity of both groups of solutes, the interested reader is referred to the reviews by Schepers et al., and Mallipattu et al. (71, 72) . Marinobufagenin belongs to the family of endogenous cardiotonic steroids (CTS), also known as digitalis-like factors, and is produced by adrenal cortical cells (73) . MBG is a Na + /K + -ATPase inhibitor that specifically binds to the α subunit of the sodium pump. This results in renal sodium excretion, increased myocardial contractility, and vasoconstriction (73) . Therefore, CTS derived from dried toad skins were already used 1000 years ago in traditional medicine to treat congestive heart failure. Elevated levels of MGB have been detected in CKD and hemodialysis patients (74, 75) , and Fedorova et al. reported that MBG stimulated renal fibrosis in rats as well as increased tubular expression of Snail (76) . Furthermore, they demonstrated that MGB induced EMT in LLC-PK1 cells as observed by increased levels of collagen I, fibronectin, and vimentin (76) . In line with the observed profibrotic effect of MBG, it was reported that immunization against this steroid attenuated renal fibrosis in 5/6-nephrectomized rats (77) .
These thought-provoking results warrant further scrutiny and without a doubt many more uremic retention solutes may be classified as profibrotic in the near future.
Future Directions
CKD is a growing health concern and renal fibrosis is an integral part of the pathophysiological mechanism underlying disease progression. Current therapies for renal fibrosis mainly focus on the etiology of the disease, such as hypertension or diabetes, and as such show only limited efficacy in halting the fibrotic process (3) . A key feature of uremia is the accumulation of a wide array of potential toxic solutes and slowly a body of evidence is emerging implicating these retention solutes as culprits in CKDassociated (renal) fibrogenesis. Therefore, therapies aimed at limiting the intake/absorption/production of uremic solutes, such as oral adsorbents or probiotics (78) (79) (80) , or treatment modalities supporting the clearance of these compounds, e.g., living dialysis membranes (81), will most likely have a great potential for slowing fibrosis. Moreover, better understanding of the profibrotic effects of the multiplicity of uremic retention solutes will further aid in unveiling novel therapeutic targets.
Author Contributions
HM and PO conceived the manuscript. HM, ES, and RV wrote the manuscript. GG and PO critically revised and improved the manuscript writing. All authors approved the final version of the manuscript and fully agree with its content.
Funding
This work was supported by the Netherlands Organisation for Health Research and Development (ZonMW; grant number 114021010).
